ENSC - CIK 0001716947
Ensysce Biosciences, Inc. trades as ENSC. In its fiscal 2025 annual report the company posted revenue of $5.07M, down 2.8% from the prior year. This page tracks Ensysce Biosciences, Inc. through 529 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Ensysce Biosciences, Inc.'s revenue grew from $3.93M to $5.07M, a compound annual growth rate of 5.2%.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| Quarterly report | 10-Q | 2026-05-15 |
| Major company event | 8-K | 2026-05-15 |
| Employee stock plan | S-8 | 2026-04-30 |
| EFFECT | - | 2026-04-15 |
| Company correspondence | CORRESP | 2026-04-14 |
| SEC correspondence | UPLOAD | 2026-04-13 |
| Securities registration | S-3 | 2026-04-09 |
The largest companies sharing Ensysce Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).
Ensysce Biosciences, Inc. reported revenue of $5.07M for fiscal year 2025, a decrease of 2.8% year over year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.